10 results on '"Izawa, Kumi"'
Search Results
2. Identification of IgE cross-reactive allergens causing food allergies including pollen-food allergy syndrome (PFAS).
- Author
-
Yamamoto, Risa, Izawa, Kumi, Ando, Tomoaki, Kaitani, Ayako, Maehara, Akie, Nakako, Nobuhiro, and Kitaura, Jiro
- Published
- 2024
- Full Text
- View/download PDF
3. Human CD300C Delivers an Fc Receptor-γ-dependent Activating Signal in Mast Cells and Monocytes and Differs from CD300A in Ligand Recognition.
- Author
-
Takahashi, Mariko, Izawa, Kumi, Kashiwakura, Jun-ichi, Yamanishi, Yoshinori, Enomoto, Yutaka, Kaitani, Ayako, Maehara, Akie, Isobe, Masamichi, Ito, Shinichi, Matsukawa, Toshihiro, Nakahara, Fumio, Oki, Toshihiko, Kajikawa, Masunori, Ra, Chisei, Okayama, Yoshimichi, Kitamura, Toshio, and Kitaura, Jiro
- Subjects
- *
MONOCYTES , *MAST cells , *IMMUNOGLOBULINS , *CHEMOKINES , *CYTOKINES - Abstract
D300C is highly homologous with an inhibitory receptor CD300A in an immunoglobulin-like domain among the human CD300 family of paired immune receptors. To clarify the precise expression and function of CD300C, we generated antibodies discriminating between CD300A and CD300C, which recognized a unique epitope involving amino acid residues CD300A(F56-L57) and CD300C(L63-R64). Notably, CD300C was highly expressed in human monocytes and mast cells. Cross-linking of CD300C by its specific antibody caused cytokine/ chemokine production of human monocytes and mast cells. Fc receptor γ was indispensable for both efficient surface expression and activating functions of CD300C. To identify a ligand for CD300A or CD300C, we used reporter cell lines expressing a chimera receptor harboring extracellular CD300A or CD300C and intracellular CD3ζ, in which its unknown ligand induced GFP expression. Our results indicated that phosphatidylethanolamine (PE) among the lipids tested and apoptotic cells were possible ligands for both CD300C and CD300A. PE and apoptotic cells more strongly inducedGFPexpression in the reporter cells through binding to extracellular CD300A as compared with CD300C. Differential recognition of PE by extracellular CD300A and CD300C depended on different amino acid residues CD300A(F56-L57) and CD300C(L63-R64). Interestingly, GFP expression induced by extracellular CD300C-PE binding in the reporter cells was dampened by co-expression of full-length CD300A, indicating the predominance of CD300A over CD300C in PE recognition/signaling. PE consistently failed to stimulate cytokine production in monocytes expressing CD300C with CD300A. In conclusion, specific engagement of CD300C led to Fc receptor γ-dependent activation of mast cells and monocytes. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
4. Functional Analysis of Activating Receptor LMIR4 as a Counterpart of Inhibitory Receptor LMIR3.
- Author
-
Izawa, Kumi, Kitaura, Jiro, Yamanishi, Yoshinori, Matsuoka, Takayuki, Oki, Toshihiko, Shibata, Fumi, Kumagai, Hidetoshi, Nakajima, Hideaki, Maeda-Yamamoto, Man, Hauchins, Jeffrey P., Tybuiewicz, Victor L. J., Takai, Toshiyuki, and Kitamura, Toshio
- Subjects
- *
LEUCOCYTES , *CELLS , *GRANULOCYTES , *MACROPHAGES , *MAST cells , *BONE marrow - Abstract
The leukocyte mono-Ig-like receptor (LMIR) belongs to a new family of paired immunoreceptors. In this study, we analyzed activating receptor LMIR4/CLM-5 as a counterpart of inhibitory receptor LMIR3/CLM-1. LMIR4 is expressed in myeloid cells, including granulocytes, macrophages, and mast cells, whereas LMIR3 is more broadly expressed. The association of LMIR4 with Fc receptor-γ among immunoreceptor tyrosine- based activation motif-bearing molecules was indispensable for LMIR4-mediated functions of bone marrow-derived mast cells, but dispensable for its surface expression. Cross-linking of LMIR4 led to Lyn- and Syk-dependent activation of bone mar- row-derived mast cells, resulting in cytokine production and degranulation, whereas that of LMIR3 did not. The triggering of LMIR4 and TLR4 synergistically caused robust cytokine production in accordance with enhanced activation of ERK, whereas the co-ligation of LMIR4 and LMIR3 dramatically abrogated cytokine production. Notably, intraperitoneal administration of lipopolysaccharide strikingly up-regulated LMIR3 and down-regulated LMIR4, whereas that of granulocyte colony-stimulating factor up-regulated both LMIR3 and LMIR4 in granulocytes. Cross-linking of LMIR4 in bone marrow granulocytes also resulted in their activation, which was enhanced by lipopolysaccharide. Collectively, these results suggest that the innate immune system is at least in part regulated by the qualitative and quantitative balance of the paired receptors LMIR3 and LMIR4. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
5. Notch signaling contributes to the establishment of sustained unresponsiveness to food allergens by oral immunotherapy.
- Author
-
Yoneyama, Toshiyuki, Nakano, Nobuhiro, Hara, Mutsuko, Yamada, Hiromichi, Izawa, Kumi, Uchida, Koichiro, Kaitani, Ayako, Ando, Tomoaki, Kitaura, Jiro, Ohtsuka, Yoshikazu, Ogawa, Hideoki, Okumura, Ko, and Shimizu, Toshiaki
- Abstract
Oral immunotherapy (OIT) aims to establish desensitization and sustained unresponsiveness (SU) in patients with food allergy by ingestion of gradually increasing doses of specific food allergens. However, little is known about the mechanisms by which OIT induces SU to specific allergens. We investigated the role of Notch signaling, which controls cell fate decisions in many types of immune cells in the induction of SU by OIT treatment. Two types of mouse models, ovalbumin-induced food allergy and OIT, were generated. To elucidate the role of Notch signaling in OIT-induced SU, mice were intraperitoneally injected with the Notch signaling inhibitor N -[(3,5-difluorophenyl)acetyl]- l -alanyl-2-phenylglycine-1,1-dimethylethyl ester during the OIT treatment period. Ovalbumin-sensitized mice were desensitized and also had SU induced by OIT treatment, whereas repeated challenges with ovalbumin caused the development of severe allergic reactions in ovalbumin-sensitized mice. Administration of N -[(3,5-difluorophenyl)acetyl]- l -alanyl-2-phenylglycine-1,1-dimethylethyl ester to mice during the OIT treatment period inhibited the establishment of SU to ovalbumin but did not affect the induction of desensitization. OIT induced a systemic expansion of IL-10–producing CD4
+ T cells, including T H 2 cells, and myeloid-derived suppressor cells (MDSCs), particularly the monocytic MDSC subpopulation. Inhibition of Notch signaling prevented the OIT-induced expansion of those cells. In vitro cultures of bone marrow cells showed that Notch signaling directly promoted the generation of monocytic MDSCs. In addition, the contribution of MDSCs to OIT-induced SU was confirmed by MDSC depletion with the anti-Gr1 antibody. Notch signaling contributes to the establishment of SU induced by OIT through systemic expansion of immunosuppressive cells, such as IL-10–producing CD4+ T cells and MDSCs. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
6. Identification of inhibitory mechanisms in pseudo-allergy involving Mrgprb2/MRGPRX2-mediated mast cell activation.
- Author
-
Takamori, Ayako, Izawa, Kumi, Kaitani, Ayako, Ando, Tomoaki, Okamoto, Yoko, Maehara, Akie, Tanabe, Atsushi, Nagamine, Masakazu, Yamada, Hiromichi, Uchida, Shino, Uchida, Koichiro, Isobe, Masamichi, Hatayama, Tomoki, Watanabe, Daiki, Ando, Taiki, Ide, Takuma, Matsuzawa, Moe, Maeda, Keiko, Nakano, Nobuhiro, and Tamura, Naoto
- Published
- 2019
- Full Text
- View/download PDF
7. Sphingomyelin and ceramide are physiological ligands for human LMIR3/CD300f, inhibiting FcεRI-mediated mast cell activation.
- Author
-
Izawa, Kumi, Isobe, Masamichi, Matsukawa, Toshihiro, Ito, Shinichi, Maehara, Akie, Takahashi, Mariko, Yamanishi, Yoshinori, Kaitani, Ayako, Oki, Toshihiko, Okumura, Ko, Kitamura, Toshio, and Kitaura, Jiro
- Published
- 2014
- Full Text
- View/download PDF
8. Characterization of Leukocyte Mono-immunoglobulin-like Receptor 7 (LMIR7)/CLM-3 as an Activating Receptor.
- Author
-
Enomoto, Yutaka, Yamanishi, Yoshinori, Izawa, Kumi, Kaitani, Ayako, Takahashi, Mariko, Maehara, Akie, Oki, Toshihiko, Takamatsu, Reiko, Kajikawa, Masunori, Takai, Toshiyuki, Kitamura, Toshio, and Kitaura, Jiro
- Subjects
- *
IMMUNOGLOBULINS , *LEUCOCYTES , *AMINO acid sequence , *FLOW cytometry , *NEUTROPHILS , *MAST cells - Abstract
Here we characterize leukocyte mono-Ig-like receptor 7 (LMIR7)/CLM-3 and compare it with an activating receptor, LMIR4/CLM-5, that is a counterpart of an inhibitory receptor LMIR3/CLM-1. LMIR7 shares high homology with LMIR4 in the amino acid sequences of its Ig-like and transmembrane domains. Flow cytometric analysis demonstrated that LMIR4 was predominantly expressed in neutrophils, whereas LMIR7 was highly expressed in mast cells and monocytes/macrophages. Importantly, LMIR7 engagement induced cytokine production in bone marrow-derived mast cells (BMMCs). Although FcRγ deficiency did not affect surface expression levels of LMIR7, it abolished LMIR7-mediated activation of BMMCs. Consistently we found significant interaction of LMIR7-FcRγ, albeit with lower affinity compared with that of LMIR4-FcRγ. Our results showed that LMIR7 transmits an activating signal through interaction with FcRγ. In addition, like LMIR4, LMIR7 synergizes with TLR4 in signaling. Analysis of several chimera receptors composed of LMIR4 and LMIR7 revealed these findings: 1) the transmembrane of LMIR7 with no charged residues maintained its surface expression at high levels in the absence of FcRγ, 2) the extracellular juxtamembrane region of LMIR7 had a negative effect on its surface expression levels; and 3) the strong interaction of LMIR4 with FcRγ depended on the extracellular juxtamembrane region as well as the transmembrane domain of LMIR4. Thus, LMIR7 shares similarities with LMIR4, although they are differentially regulated in their distribution, expression, and function. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
9. A C-terminal mutant of CCAAT-enhancer-binding protein α (C/EBPα-Cm) downregulates Csf1r, a potent accelerator in the progression of acute myeloid leukemia with C/EBPα-Cm.
- Author
-
Togami, Katsuhiro, Kitaura, Jiro, Uchida, Tomoyuki, Inoue, Daichi, Nishimura, Koutarou, Kawabata, Kimihito C., Nagase, Reina, Horikawa, Sayuri, Izawa, Kumi, Fukuyama, Tomofusa, Nakahara, Fumio, Oki, Toshihiko, Harada, Yuka, Harada, Hironori, Aburatani, Hiroyuki, and Kitamura, Toshio
- Subjects
- *
GENETIC mutation , *CCAAT enhancer binding proteins , *ACUTE myeloid leukemia , *DISEASE progression , *LEUCINE zippers - Abstract
Two types of CCAAT-enhancer-binding protein α (C/EBPα) mutants are found in acute myeloid leukemia (AML) patients: N-terminal frame-shift mutants (C/EBPα-N m ) generating p30 as a dominant form and C-terminal basic leucine zipper domain mutants (C/EBPα-C m ). We have previously shown that C/EBPα-K304_R323dup belonging to C/EBPα-C m , but not C/EBPα-T60fsX159 belonging to C/EBPα-N m , alone induced AML in mouse bone marrow transplantation (BMT) models. Here we show that various C/EBPα-C m mutations have a similar, but not identical, potential in myeloid leukemogenesis. Notably, like C/EBPα-K304_R323dup, any type of C/EBPα-C m tested (C/EBPα-S299_K304dup, K313dup, or N321D) by itself induced AML, albeit with different latencies after BMT; C/EBPα-N321D induced AML with the shortest latency. By analyzing the gene expression profiles of C/EBPα-N321D- and mock-transduced c-kit + Sca-1 + Lin − cells, we identified Csf1r as a gene downregulated by C/EBPα-N321D. In addition, leukemic cells expressing C/EBPα-C m exhibited low levels of colony stimulating factor 1 receptor in mice. On the other hand, transduction with C/EBPα-N m did not influence Csf1r expression in c-kit + Sca-1 + Lin − cells, implying a unique role for C/EBPα-C m in downregulating Csf1r . Importantly, Csf1r overexpression collaborated with C/EBPα-N321D to induce fulminant AML with leukocytosis in mouse BMT models to a greater extent than did C/EBPα-N321D alone. Collectively, these results suggest that C/EBPα-C m -mediated downregulation of Csf1r has a negative, rather than a positive, impact on the progression of AML involving C/EBPα-C m , which might possibly be accelerated by additional genetic and/or epigenetic alterations inducing Csf1r upregulation. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
10. Hes1 upregulation contributes to the development of FIP1L1-PDGRA–positive leukemia in blast crisis.
- Author
-
Uchida, Tomoyuki, Kitaura, Jiro, Nakahara, Fumio, Togami, Katsuhiro, Inoue, Daichi, Maehara, Akie, Nishimura, Koutarou, Kawabata, Kimihito C., Doki, Noriko, Kakihana, Kazuhiko, Yoshioka, Kosuke, Izawa, Kumi, Oki, Toshihiko, Sada, Akiko, Harada, Yuka, Ohashi, Kazuteru, Katayama, Yoshio, Matsui, Toshimitsu, Harada, Hironori, and Kitamura, Toshio
- Subjects
- *
GENE expression , *GENE enhancers , *CHRONIC myeloid leukemia , *PLATELET-derived growth factor receptors , *EOSINOPHILIA , *MYELOPROLIFERATIVE neoplasms , *BONE marrow transplantation , *LABORATORY mice - Abstract
We have previously shown that elevated expression of Hairy enhancer of split 1 (Hes1) contributes to blast crisis transition in Bcr-Abl–positive chronic myelogenous leukemia. Here we investigate whether Hes1 is involved in the development of other myeloid neoplasms. Notably, Hes1 expression was elevated in only a few cases of 65 samples with different types of myeloid neoplasms. Interestingly, elevated expression of Hes1 was found in two of five samples of Fip1-like1 platelet-derived growth factor receptor-α (FIP1L1-PDGFA)-positive myeloid neoplasms associated with eosinophilia. Whereas FIP1L1-PDGFRα alone induced acute T-cell leukemia or myeloproliferative neoplasms in mouse bone marrow transplantation models, mice transplanted with bone marrow cells expressing both Hes1 and FIP1L1-PDGFRα developed acute leukemia characterized by an expansion of myeloid blasts and leukemic cells without eosinophilic granules. FIP1L1-PDGFRα conferred cytokine-independent growth to Hes1-transduced common myeloid progenitors, interleukin-3–dependent cells. Imatinib inhibited the growth of common myeloid progenitors expressing Hes1 with FIP1L1-PDGFRα, but not with imatinib-resistant FIP1L1-PDGFRα mutants harboring T674I or D842V. In contrast, ponatinib efficiently eradicated leukemic cells expressing Hes1 and the imatinib-resistant FLP1L1-PDGFRΑ mutant in vitro and in vivo. Thus, we have established mouse models of FIP1L1-PDGFRA-positive leukemia in myeloid blast crisis, which will help elucidate the pathogenesis of the disease and develop a new treatment for it. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.